Home page A B C D E F G H I K L M N O P Q R S T U V W X Y Z

Zolpidem use



Zolpidem use and motor vehicle collisions in older drivers

8.14.2017 | Jennifer Bargeman

Sleep Med. 2016 Apr;20:98-102. doi: 10.1016/j.sleep.2015.12.004. Epub 2015 Dec 29. Zolpidem use and motor vehicle collisions in older drivers. Booth JN.

The participant's five-year MVC history was determined from Alabama Department of Public Safety accident reports. Participants were current drivers aged ≥70 years residing in north-central Alabama, spoke English, had a valid driver's license, and had driven within the past three months (n = 2000). Current zolpidem use was determined by pill bottle review. The five-year MVC and at-fault MVC rate ratios (RR) were estimated comparing zolpidem users with nonusers in the overall sample and a priori-defined age and sex subgroups.

Current zolpidem users, specifically women and individuals aged 80 years or more, had higher MVC rates than nonusers.

Risk of Parkinson's disease following zolpidem use a retrospective

9.15.2017 | Logan Blare

J Clin Psychiatry. 2015 Jan;76(1):e104-10. doi: 10.4088/JCP.13m08790. Risk of Parkinson's disease following zolpidem use: a retrospective, population-based.

To evaluate the influence of long-term zolpidem use on the incidence of developing Parkinson's disease.

The risk of Parkinson's disease increased with increasing zolpidem dose, with an HR of 0.70 for low-dose users (< 400 mg/y) and 2.94 for high-dose users (≥ 1,600 mg/y). The overall incidence of Parkinson's disease was greater among zolpidem users than in the comparison cohort (HR = 1.88; 95% CI, 1.45-2.45). However, there was no difference in Parkinson's disease incidence between these 2 cohorts after 5 years of observation.

Modafinil and zolpidem use by emergency medicine residents

6.12.2017 | Logan Miers
Zolpidem use

OBJECTIVES: The objective was to assess the prevalence and patterns of modafinil and zolpidem use among emergency medicine (EM) residents and describe.

Zolpidem use is common among EM residents, with most users initiating use during residency. Side effects are commonly reported for both of these agents, and long-term safety remains unclear. Modafinil use is relatively uncommon, although most residents using have also initiated use during residency.

National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA. National Center for Biotechnology Information, U.S.

A voluntary, anonymous survey was distributed in February 2006 to EM residents nationally in the context of the national American Board of Emergency Medicine in-training examination. Data regarding frequency and timing of modafinil and zolpidem use were collected, as well as demographic information, reasons for use, side effects, and perceived dependence.

Warning: The NCBI web site requires JavaScript to function. more.

Generate a file for use with external citation management software.

The objective was to assess the prevalence and patterns of modafinil and zolpidem use among emergency medicine (EM) residents and describe side effects resulting from use.

Past modafinil use was reported by 2.4% (57/2,372) of EM residents, with 66.7% (38/57) of those using modafinil having initiated their use during residency. Side effects were commonly reported by modafinil users (31.0%)-most frequent were palpitations, insomnia, agitation, and restlessness. The response rate was 56% of the total number of EM residents who took the in-training examination (2,397/4,281). Zolpidem users reported side effects (22.6%) including drowsiness, dizziness, headache, hallucinations, depression/mood lability, and amnesia. A total of 324 of 516 (62.8%) of zolpidem users initiated use during residency. A total of 133 of 134 residency programs distributed the surveys (99%). Past zolpidem use was reported by 21.8% (516/2,367) of EM residents, with 15.3% (362/2,367) reporting use in the past year and 9.3% (221/2,367) in the past month.

Zolpidem use and risk of fractures a systematic review and meta

12.18.2017 | Logan Miers
Zolpidem use

Osteoporos Int. 2016 Oct;27(10):2935-44. doi: 10.1007/s . Epub 2016 Apr 22. Zolpidem use and risk of fractures: a systematic review and.

Previous studies have reported inconsistent findings regarding the association between the use of zolpidem and the risk of fractures. We performed a systematic literature review and meta-analysis to assess the association.

Fracture; Hypnotics; Meta-analysis; Non-benzodiazepine; Zolpidem.

Generate a file for use with external citation management software.

Recent epidemiologic studies have reported increased fracture risk in patients taking zolpidem, but the results have been inconsistent. The present meta-analysis shows that the use of zolpidem is associated with an increased risk of fractures. Zolpidem is a representative of non-benzodiazepine hypnotics.

Clinicians should be cautious when prescribing zolpidem for patients at high risk of fracture. The use of zolpidem may increase the risk of fractures.

National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA.

A total of 1,092,925 participants (129,148 fracture cases) were included from 9 studies (4 cohort, 4 case-control, and 1 case-crossover study). Overall, the use of zolpidem was associated with an increased risk of fracture (relative risk 1.92, 95 % CI 1.65-2.24; I (2) = 50.9 %). Of note, the risk for hip fracture was higher than that for fracture at any site (hip fracture, RR 2.80, 95 % CI 2.19-3.58; fracture at any site, RR 1.84, 95 % CI 1.67-2.03; P < 0.001). High-quality subgroups (cohort studies, high NOS score, adjusted for any confounder, or adjusted for osteoporosis) had higher RRs than the corresponding low-quality subgroups (high quality, 1.94-2.76; low quality, 1.55-1.79).

Warning: The NCBI web site requires JavaScript to function. more.

Methodological quality was assessed based on the Newcastle-Ottawa Scale (NOS). We identified relevant studies by searching MEDLINE, EMBASE, Cochrane Library, and PsycINFO without language restrictions (until August 2014).

Zolpidem Use Associated With Increased Risk of Pyogenic Liver

11.17.2017 | Nathan Becker
Zolpidem use

Zolpidem Use Associated With Increased Risk of Pyogenic Liver Abscess: A Case-Control Study in Taiwan. Liao KF(1), Lin CL, Lai SW, Chen WC.

The adjusted OR decreased to 0.85 for those with late use of zolpidem (95% CI 0.70, 1.03), but without statistical significance.Current use of zolpidem is associated with the increased risk of pyogenic liver abscess. Patients whose last remaining 1 tablet for zolpidem was noted >7 days before the date of admission for pyogenic liver abscess were defined as late use of zolpidem. The purpose of this study was to explore the association between zolpidem use and pyogenic liver abscess in Taiwan.This was a population-based case-control study using the database of the Taiwan National Health Insurance Program since 2000 to 2011. A multivariable unconditional logistic regression model was used to measure the odds ratio (OR) and 95% confidence interval (CI) to explore the association between zolpidem use and pyogenic liver abscess.After adjustment for possible confounding variables, the adjusted OR of pyogenic liver abscess was 3.89 for patients with current use of zolpidem (95% CI 2.89, 5.23), when compared with those with never use of zolpidem. Physicians should take the risk of pyogenic liver abscess into account when prescribing zolpidem. Patients whose last remaining 1 tablet for zolpidem was noted ≤7 days before the date of admission for pyogenic liver abscess were defined as current use of zolpidem. We identified 1325 patients aged 20 to 84 years with the first-attack of pyogenic liver abscess as the cases, and 5082 patients without pyogenic liver abscess matched with sex, age, comorbidities, and index year of hospitalization for pyogenic liver abscess as the controls. Patients who never received 1 prescription for zolpidem were defined as never use of zolpidem.

National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA.

Generate a file for use with external citation management software.

Warning: The NCBI web site requires JavaScript to function. more.